Navigation Links
Hypertension Diagnostics Announces Fiscal Year 2007 Results
Date:9/27/2007

June 30

2007 2006 2007 2006

Revenue:

Equipment sales $ 379,100 $ 209,500 $ 1,593,706 $ 1,352,486

Equipment rental 56,707 84,769 255,247 418,979

Service/contract

income 2,674 1,267 29,887 18,081

438,481 295,536 1,878,840 1,789,546

Cost of Sales 18,939 1,483 66,413 90,447

Gross Profit 419,542 294,053 1,812,427 1,699,099

Expenses:

Selling, general

and administrative 447,678 685,958 2,381,310 3,018,624

Total Expenses 447,678 685,958 2,381,310 3,018,624

Operating Loss (28,136) (391,905) (568,883) (1,319,525)

Other Income:

Interest income 14,558 16,338 56,773 46,783

Gain on sale of

property and

equipment - - 8,099 -

Total Other

Income 14,558 16,338 64,872 46,783

Net Loss $ (13,578) $ (375,567) $ (504,011) $(1,272,742)

Basic and Diluted

Net Loss

per Share $ (.00) $ (.01) $ (.01) $ (.04)

Weighted Average

Shares

Outstanding 39,620,262 39,714,469 39,793,320 35,219,474

Balance Sheet Data

June 30, 2007 June 30, 2006

Cash and cash

equivalents $ 1,376,632 $ 1,722,913

Total current assets 1,976,825 2,257,390

Total assets 2,020,385 2,345,949

Total current liabilities 582,124
'/>"/>

SOURCE Hypertension Diagnostics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. New viewpoint on Hypertension
3. Hypertension drugs could lower Disability
4. Preventing white coat hypertension
5. New drug for hypertension
6. FDA Approves Remodulin for Pulmonary Hypertension
7. Risk of dementia reduced hypertension drugs
8. Glaucoma & Ocular Hypertension more likely in patients with refractive errors
9. Hypertension lowered by Bedtime Dosing
10. An hour of exercise a week cuts hypertension
11. Better Treatment For Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... Conn., July 24 /PRNewswire/ -- People think it,s ...ffer many opportunities to eat right,and stay fit....t menu,selections, so if you order carefully your ...o: http://www.newscom.com/cgi-bin/prnh/20071212/N...mptation, you,ll want to stay,away from the cruise...
(Date:7/24/2008)... Greater access for people with disab...oad on ,Social Security disability system. , ...24, 2008 -- With the signing of the Americans with...n in the lives of people with disabilities and the... gained better access to methods that help them im...
(Date:7/24/2008)... A cleanroom manufacturing company ha...cleanrooms. The feature is a utility panel which ...hance the cleanroom appearance. , ...- Gerbig Engineering, a designer, fabricator and i...t they are now offering a utility panel for integr...
(Date:7/24/2008)... As America's baby boomers age, ...itions such as diabetes that necessitate the use o...t bracelet jewelry gives a generation attractive i...mation. , (PRWEB) July 24...tening health conditions can make a statement in m...
Breaking Medicine News(10 mins):Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Treat Yourself To a Healthy Cruise 2Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Treat Yourself To a Healthy Cruise 3Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 2Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 3Health News:Gerbig Engineering Announces Availability of Cleanroom Utility Panel 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 3
Life After Death: Organ Donation
...the first study to show that even mildly abnormal ...n elderly men undergoing major surgery," said Dr. ...dical Center and Brown University in Rhode Island....rovidence Veterans Affairs Medical Center and The ...
...s at the University of California, Riverside have ...nces, for two key proteins in the 'dragline silk' ...ad to a variety of new materials for industrial, m...dow spiders dragline silk is a standout compared t...
...-Hajam carefully placed the glass jars over the sl...n to pump out the air. In the ensuing vacuum , the... into the clear containers. "The Assyrians, the C... used to practice cupping to draw out the corrupt ...
Other Medicine News:Health News:Life After Death: Organ Donation 2Health News:Life After Death: Organ Donation 3Health News:Abnormality in the Red Blood Count Cell Poses High Risks 2Health News:Genetic Secrets Behind the Dragline Silk 2Health News:Ancient Healing Technique Gains New Popularity in Iraq 2
(Date:7/22/2008)... Two Regimens Including Lantus(R) and Apidra(R) R...nts with Type 2 Diabetes, Whatever the Algorithm ..., N.J., July 22 /- Results from the "... a Simple Algorithm to Carbohydrate,Counting for A...re,published in the American Diabetes Association,...
(Date:7/22/2008)...est Developed and Validated by Columbia University...s, Proprietary MicroRNA Technology, The Test Dif...ell Lung Cancer (NSCLC), Classifying Squamous-Cel... 96 Percent and Specificity of 90 Percent,This is ...RNAs, Sensitivity as Biomarkers for Accur...
(Date:7/22/2008)... A Pilot Study Suggests That Ekkyo,s New Approach ...tically Improve Scar Healing Physiology, MARSEILL...y known as,Heatwave Technology) a photomedicine co...ystems for skin scar prevention and reduction, ann...le in Lasers in Surgery and Medicine*,reporting th...
(Date:7/21/2008)... LONDON, July 21 /- The SEAS (Simva... investigated the effects of intensive,cholesterol...mg daily) and,ezetimibe (10 mg daily) in patients ...olves partial blockage of the aortic valve in,the ...people in Western,populations. Left untreated, it ...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4Clarient Reports First Quarter 2008 18095 1Clarient Reports First Quarter 2008 18095 2Clarient Reports First Quarter 2008 18095 3Clarient Reports First Quarter 2008 18095 4Clarient Reports First Quarter 2008 18095 5Clarient Reports First Quarter 2008 18095 6Clarient Reports First Quarter 2008 18095 7Clarient Reports First Quarter 2008 18095 8Patient Safety Authority Issues Annual Report for 2007 18091 1Patient Safety Authority Issues Annual Report for 2007 18091 2Patient Safety Authority Issues Annual Report for 2007 18091 3Patient Safety Authority Issues Annual Report for 2007 18091 4Patient Safety Authority Issues Annual Report for 2007 18091 5Patient Safety Authority Issues Annual Report for 2007 18091 6Patient Safety Authority Issues Annual Report for 2007 18091 7Patient Safety Authority Issues Annual Report for 2007 18091 8Patient Safety Authority Issues Annual Report for 2007 18091 9Patient Safety Authority Issues Annual Report for 2007 18091 10Patient Safety Authority Issues Annual Report for 2007 18091 11Patient Safety Authority Issues Annual Report for 2007 18091 12Patient Safety Authority Issues Annual Report for 2007 18091 13Patient Safety Authority Issues Annual Report for 2007 18091 14Patient Safety Authority Issues Annual Report for 2007 18091 15Patient Safety Authority Issues Annual Report for 2007 18091 16Patient Safety Authority Issues Annual Report for 2007 18091 17Patient Safety Authority Issues Annual Report for 2007 18091 18Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 1Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 2Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 3Neurocrine Biosciences Reports First Quarter 2008 Results 1949 1Neurocrine Biosciences Reports First Quarter 2008 Results 1949 2Neurocrine Biosciences Reports First Quarter 2008 Results 1949 3Neurocrine Biosciences Reports First Quarter 2008 Results 1949 4Neurocrine Biosciences Reports First Quarter 2008 Results 1949 5Neurocrine Biosciences Reports First Quarter 2008 Results 1949 6Neurocrine Biosciences Reports First Quarter 2008 Results 1949 7Neurocrine Biosciences Reports First Quarter 2008 Results 1949 8
... - Algeta ASA (OSE: ALGETA), the,Norwegian cancer ...lash;yvind Bruland, of the Norwegian Radium Hospit...ter and Discussion entitled,"Radium-223 in the tr...cancer (HRPC): Results from a randomized,placebo-...ty of,Clinical Oncology,s annual meeting (1-5 June...
...NESS WIRE)--May 29, 2007 - Gilead,Sciences, Inc. (...R-CF1 (CP-AI-007) study of aztreonam lysine for in...ibrosis (CF) who have,pulmonary Pseudomonas aerugi...oint of change at Day 28 from baseline in respirat...uestionnaire-Revised,(CFQ-R), a patient-reported o...
Other Medicine Technology:Algeta to Present Phase II Clinical Study Data for Alpharadin in,Prostate Cancer at ASCO 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
Medicine Products: